Editors for Cancer Biology
Senior editors
-
Utpal Banerjee
University of California, Los Angeles, United States
Utpal Banerjee is the Irving and Jean Stone Professor and Chair of the Department of Molecular, Cell and Developmental Biology at the University of California, Los Angeles, with a joint appointment in the Department of Biological Chemistry at the David Geffen School of Medicine. He also serves as Co-Director of the Broad Stem Cell Research Center and as Director of the UCLA Interdepartmental Minor in Biomedical Research. He is a member of UCLA’s Jonsson Comprehensive Cancer Center and is affiliated with the Brain Research Institute and the Neuroscience Graduate Program.
Banerjee’s laboratory has worked on several oncogenic and metabolic signals that are important in development and disease. The lab studies the effects of systemic signals on the maintenance of blood progenitors in Drosophila, and the role of metabolic pathways in the control of proliferation and differentiation in the preimplantation mouse embryo.
- Expertise
- Developmental Biology
- Stem Cells and Regenerative Medicine
- Cancer Biology
- Research focus
- haematopoiesis
- cancer biology
- Experimental organism
- D. melanogaster
- mouse
-
Wafik S El-Deiry
Brown University, United States
Wafik El-Deiry, MD, PhD, FACP is Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Director, Cancer Center at Brown University, and Director of the Joint Program in Cancer Biology at Brown and Lifespan. He is a Professor of Pathology and Laboratory Medicine, Professor of Medical Science, and Mencoff Family University Professor at Brown. He sees patients in his weekly clinic at Rhode Island Hospital focused on care of patients with colorectal cancer and participates in clinical trials based on his laboratory’s research on novel therapeutics. He previously served as Deputy Director for Translational Research, co-Leader of the Molecular Therapeutics Program, Professor of Oncology, and the William Wikoff Smith Endowed Chair in Cancer Research at Fox Chase Cancer Center. From 2010 through 2014 Dr El-Deiry was the Rose Dunlap Professor of Medicine and Chief of Hematology-Oncology at Penn State. In 2009, El-Deiry became an American Cancer Society Research Professor. He was previously a tenured Professor of Medicine (Hematology-Oncology), Genetics, and Pharmacology at University of Pennsylvania, co-Leader of the Radiobiology and Imaging Program at the Abramson Cancer Center and Associate Director for Physician-Scientist Training in Hematology-Oncology when he left Penn in 2010. He earned MD/PhD degrees from University of Miami School of Medicine and completed internal medicine residency and medical oncology fellowship at the Johns Hopkins Hospital and the Johns Hopkins Oncology Center. As a practicing academic Oncologist, his scientific interest and expertise is in cell death, drug resistance in cancer and drug discovery and development. El-Deiry founded two companies, Oncoceutics, Inc. and p53-Therapeutics, Inc.
El-Deiry discovered p21(WAF1) as a p53 target gene, universal cell cycle inhibitor, and tumor suppressor gene that for the first time explained the mammalian cell stress response. He discovered TRAIL receptor DR5 and its regulation by p53. TRAIL is part of the host immune system that suppresses cancer and its metastases. His lab created a knock-out mouse for TRAIL receptor DR5 and this mouse is tumor prone and develops an inflammatory syndrome in the lungs and gut after sub-lethal irradiation. He identified c-Myc as a major determinant of TRAIL sensitivity and demonstrated synergy between TRAIL therapy and multi-kinase inhibitor sorafenib. Building on his prior accomplishments, El-Deiry discovered ONC201/TIC10 as a first-in-class TRAIL pathway inducer that is orally bioavailable and crosses the blood-brain barrier to treat brain tumors. TRAIL and Foxo3a are required for the anti-tumor effect of ONC201 through dual blockade of ERK and Akt kinases that promotes the nuclear translocation of the Foxo3a transcription factor which directly regulates the TRAIL gene. Data from El-Deiry’s lab identified that ONC201 induces TRAIL receptor DR5 through an integrated stress response involving ATF4 and CHOP transcription factors. Patients with among the most aggressive gliomas (H3K27M mutant DIPG) have had exceptional responses to ONC201.
As a physician-scientist, Dr El-Deiry has worked to bring new discoveries to the clinic. He is committed in the next phase of his career to unraveling the mechanisms involved in p53 pathway restoration by candidate therapeutics his lab has discovered. This is exciting as he is defining a novel class of anti-cancer drugs with p53 pathway restoration and S-phase checkpoint targeting and recognizing ATF4 as a major transcription factor mechanism for p53 pathway restoration in p53-null or p53 mutant tumor cells. He is establishing transcriptomic and proteomic data sets with chemotherapy that acts through p53, and with novel small molecules that restore the p53 pathway in p53-deficient or mutant p53 expressing cells. He is exploiting medicinal chemistry and organoid technologies to perform his translational science that is leading to clinical trials some of which he leads. Dr El-Deiry conducts basic and translational clinical oncology therapeutics research through funded NIH grants, Foundations and industry. He is a member of the ASCI, AAP, Past President of the Interurban Clinical Club, previous Chair of ASCO’s Tumor Biology Track, and past Chair of an NIH Study Section on Cancer Therapeutics. Dr El-Deiry has trained many students and post-doctoral fellows, physician-scientists, and continues to mentor junior scientists and faculty in basic and translational cancer research.
- Expertise
- Medicine
- Cancer Biology
- Research focus
- cancer
- tumor suppressor genes
- colorectal cancer
- p53 pathway
- cell death
- medical oncology
- drug development
- drug discovery
- p21(WAF1)
- ONC201/TIC10
- physician-scientist issues
- Experimental organism
- human
- mouse
- Competing interests statement
- Dr El-Deiry receives funding from the NIH/NCI, the Warren Alpert Foundation, and D&D Pharmatech. He is a Specialty Chief Editor for the Cancer Molecular Targets and Therapeutics Section of Frontiers in Oncology. He is also a Section Editor for Molecular Oncology and HemOnc Today. Dr El-Deiry is the scientific founder and shareholder of Oncoceutics, Inc.
and p53-Therapeutics, Inc.
-
Eduardo Franco
McGill University, Canada
Eduardo Franco is Professor and Chairman, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal. He holds BSc (1975) and Licentiate (1976) degrees in biology from Universidade de Campinas, Brazil, and master's (MPH) and doctoral (DrPH) degrees in public health microbiology from the University of North Carolina at Chapel Hill (1981-84). He was a Guest Researcher at the US Centers for Disease Control in Atlanta (1980-81 and 1983-84), and a post-doctoral fellow in cancer epidemiology during 1984 at the International Agency for Research on Cancer in Lyon, France, at the US National Cancer Institute (NCI) in Bethesda, and at Louisiana State University, in New Orleans. Since 1985, he has conducted epidemiologic research on the causes of cancer and on the means to prevent it or to improve patient survival. He is mostly known for his contributions to our understanding of human papillomavirus infection as the cause of cervical cancer and using this knowledge to prevent this cancer via vaccination and improved screening strategies. He received the Canadian Cancer Research Alliance’s Distinguished Service to Cancer Research Award, Lifetime Achievement Awards from the American Society for Colposcopy and Cervical Pathology and from the International Papillomavirus Society, the Women in US Government’s Leadership Award, the Canadian Cancer Society’s Warwick Prize, the Geoffrey Howe Outstanding Contribution Award from the Canadian Society for Epidemiology and Biostatistics, the University of British Columbia’s Chew Wei Memorial Prize in Cancer Research, and the McLaughlin-Gallie Award from the Royal College of Physicians of Canada. He has mentored 115 graduate students and post-doctoral fellows, and 30 undergraduate trainees. He is Officer of the Order of Canada and Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences. Heholds an honorary doctorate from Universidade Fernando Pessoa, Porto, Portugal.
- Expertise
- Cancer Biology
- Epidemiology and Global Health
- Medicine
- Research focus
- cancer epidemiology
- cancer prevention
- human papillomavirus
- cancer screening
- Experimental organism
- human
- Competing interests statement
- Entire research program funded by the Medical Research Council of Canada (until 1999), Canadian Institutes of Health Research (CIHR) (1999-present), National Institutes of Health, Canadian Cancer Society, and Cancer Research Society. He has received salary awards from the Fonds de Recherche Quebec Santé and CIHR. He holds a James McGill Professorship and the Minda de Gunzburg Endowed Chair at McGill University. He serves as Editor-in-Chief for Preventive Medicine and Preventive Medicine Reports and serves on the editorial boards of Cancer Epidemiology, Biomarkers & Prevention, International Journal of Cancer, Papillomavirus Research, and Salud Publica de Mexico. He has served as occasional consultant to companies involved with HPV vaccination (Merck and GSK) and HPV diagnostics (Roche, Abbott, Qiagen, and BD).
-
Erica Golemis
Fox Chase Cancer Center, United States
Erica A Golemis, PhD is a Professor at Fox Chase Cancer Center (FCCC), and Adjunct Professor at the Temple University School of Medicine, the University of Pennsylvania, and the Drexel University College of Medicine. Since 2008, she has served as Co-Leader for the FCCC Molecular Therapeutics program, and as Deputy Chief Science Officer at FCCC. She is an elected Fellow of the American Association for the Advancement of Science, and holds the William Wikoff Smith Chair in Biology at Fox Chase. Dr Golemis joined FCCC in 1993, after completing graduate training in mechanisms of leukemogenesis at MIT, and postdoctoral work at Harvard Medical School and Massachusetts General Hospital leading to the development of new technology for the identification and analysis of protein interaction networks. One focus of her reserch is the targeted study of a group of oncogenes including NEDD9, AURKA, and associated proteins that regulate cell cycle and metastasis; this work has recently focused on defining non-canonical activities of these proteins in control of ciliation as a mechanism for their oncogenic effect. A second research area is the use of bioinformatics-guided and siRNA screening approaches to elucidate signaling networks that can be targeted to improve therapeutic response; this work is typically highly collaborative with clinical researchers. In the past 25 years, she has served continuously on peer-review panels for the NIH, the American Cancer Society, the DOD, the Komen Foundation, and other agencies.
- Expertise
- Cancer Biology
- Cell Biology
- Research focus
- signal transduction
- targeted therapy
- mitosis
- cilia
- polycystic kidney disease
- colorectal cancer
- head and neck cancer
- invasion
- metastasis
- Competing interests statement
- Dr Golemis currently receives funding from the National Institutes of Health (NIH) and holds editorial roles at the following journals: Cancer Biology and Therapy, Frontiers in Oncology, Gene and BMC Cancer.
-
Maureen Murphy
The Wistar Institute, United States
Maureen E. Murphy, Ph.D., is a Professor and Program Leader in the Molecular and Cellular Oncogenesis Program of The Wistar Institute. Dr. Murphy joined Wistar in 2011 and became a Program Leader in early 2012. She is also an adjunct professor at Drexel University College of Medicine and The Perelman School of Medicine at the University of Pennsylvania. Previously, Dr. Murphy was a professor at the Fox Chase Cancer Center. Since 1999, she has received continuous support from the National Cancer Institute (NCI) for her research on the p53 tumor suppressor protein and the HSP70 molecular chaperone.
A noted expert in the role of the p53 gene in cancer, Dr. Murphy’s laboratory focuses on how p53 functions to suppress tumor development. Through her lab’s work, Dr. Murphy is investigating the genetics of cancer health disparities. In efforts to improve precision medicine, her group is performing drug screens on tumor cells containing this variant, with the goal of finding drugs that will kill these cells preferentially. For her work on p53, Dr. Murphy is the recipient of the 2016 Gateway for Cancer Research Leadership in Cancer Advocacy Award. Murphy’s group also studies the stress-induced protein HSP70. With the knowledge that HSP70 is overexpressed in late stage cancers, Dr. Murphy’s group has pioneered the use of inhibitors of HSP70 for cancer therapy, particularly metastatic melanoma. For this effort, in 2014 her group won a Discovery Fast Track award from GlaxoSmithKline for the development of HSP70 inhibitors for cancer therapy.
In addition to her research, Dr. Murphy also plays pivotal administrative roles as Wistar’s Associate Vice President for Faculty Affairs, the Principal Investigator of its Training Grant in Basic Cancer Research, the head of the Junior Faulty Mentoring program, and the Director of its Postdoctoral Training Program. A member of the NCI’s Cancer and Molecular Pathology (CAMP) federal grant review committee, Dr. Murphy has also reviewed grants for the New Jersey Commission for Cancer Research, the Department of Defense, and Alex’s Lemonade Stand Foundation for Pediatric Cancer Research.
Dr. Murphy earned a Bachelor of Science degree in biochemistry at Rutgers University, followed by a doctorate in molecular biology at the University of Pennsylvania School of Medicine. In 1994, she began postdoctoral research at Princeton University in the laboratory of Arnold J. Levine, Ph.D., a co-discoverer of p53 and a pioneer in the field of tumor suppressor genes and cancer biology.
- Expertise
- Cancer Biology
- Research focus
- p53
- ferroptosis
- mitochondria
- colon cancer
- HSP70
- polymorphism
- Competing interests statement
- Maureen Murphy is a member of the American Association for Cancer Research (AACR). In addition to eLife, she holds editorial positions at Cancer Biology and Therapy (Senior Editor), Cancer Research (Senior Editor), Molecular Cancer Research and Carcinogenesis Integrative Research. She is a member of the NIH NCI Cancer and Molecular Pathology federal grant review committee, and receives federal funding from the National Institutes of Health (NIH).
-
Päivi Ojala
University of Helsinki, Finland
Imperial College London, United KingdomPäivi Ojala is the Professor of Cancer Cell Biology at University of Helsinki and Chair of Viral Tumorigenesis at Imperial College London. She has made significant contributions to the Kaposi’s Sarcoma herpesvirus (KSHV) field and has more recently focused also on the role of lymphatic endothelial microenvironment on cancer cell metastasis. She has expertise in organotypic 3D co-culture models, cell-based high-content screens, protein kinase signalling and viral technologies. Her work has led to demonstration of restoration of p53 function by small molecule inhibitors as a therapeutic modality for KSHV-induced lymphomas, identification of host Pim kinases, nucleophosmin, and the p53-p21 axis as novel regulators of viral replication, and shown that KSHV infection reprograms lymphatic endothelial cells (LECs) to a new, more invasive cell type. They have also demonstrated that LEC interaction with melanoma cells leads to increased distant organ metastasis in vivo, which is dependent on MMP14, Notch3 and b1-integrin- Dr. Ojala holds a doctoral degree in Molecular Genetics from the University of Helsinki, and has received postdoctoral training at the Yale School of Medicine, CT, USA.
- Expertise
- Cancer Biology
- Microbiology and Infectious Disease
- Research focus
- human tumor viruses
- virus-host interactions
- tumor microenvironment
- metastasis
- Competing interests statement
- Päivi Ojala receives funding from the Academy of Finland, Sigrid Juselius Foundation, Cancer Foundation Finland and University of Helsinki.
-
Richard M White
Memorial Sloan Kettering Cancer Center, United States
Richard White, M.D., Ph.D, is a physician-scientist at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He is interested in basic mechanisms underlying metastasis, using the zebrafish as a model system. His work has established numerous techniques for cancer modeling and high-resolution imaging in the fish. Using these tools, the lab is focused on the cross-talk between tumor cells and the microenvironment, and how this interplay influences metastatic success. His work has revealed novel interactions between melanoma cells and adipocytes in the microenvironment, and how neural crest programs play roles in melanoma progression. He has been awarded the NIH Director’s New Innovator Award, the Pershing Square Foundation Award, and the Mark Foundation ASPIRE award.
- Expertise
- Cancer Biology
- Medicine
- Research focus
- metastasis
- melanocyte development
- neural crest
- melanoma
- adipocytes
- microenvironment
- melanocytes
- Experimental organism
- zebrafish
- Competing interests statement
- Richard White receives funding from the National Institutes of Health, the Pershing Square Sohn Foundation, the Mark Foundation, the Melanoma Research Alliance, the American Cancer Society and the Harry J. Lloyd Foundation. He receives consulting fees from N-of-One, Inc.
Reviewing editors
-
Nicholas Banovich
Translational Genomics Research Institute (TGen), United States
- Expertise
- Cancer Biology
- Genetics and Genomics
- Chromosomes and Gene Expression
- Research focus
- single cell biology
- CAR T cell therapy
- gene regulation
- pulmonary fibrosis
- quantitative trait loci
-
Frederic A Bard
Institute of Molecular and Cell Biology (A*STAR), Singapore
- Expertise
- Cell Biology
- Cancer Biology
- Research focus
- Golgi
- protein glycosylation
- signaling
- cancer
- matrix degradation
- cell migration
- Experimental organism
- human
- mouse
-
Xuetao Cao
Zhejiang University School of Medicine, China
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Medicine
- Research focus
- immunology of APCs
- TLR signalling and immune regulation
- cancer immunotherapy and gene therapy
-
Vincenzo Cerullo
University of Helsinki, Finland
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Research focus
- oncolytic viruses
- cancer vaccines
- vaccines
- tumor antigens
- Experimental organism
- human
- mouse
-
Nyasha Chambwe
St Jude Children's Research Hospital, United States
- Expertise
- Cancer Biology
- Computational and Systems Biology
- Genetics and Genomics
- Research focus
- bioinformatics
- computational biology
- cancer genomics
- population genomics
- data analysis
- Experimental organism
- human
-
Seth J Corey
Cleveland Clinic, United States
- Expertise
- Cancer Biology
- Medicine
- Research focus
- myeloid malignancies
- inherited or acquired bone marrow failure
- neutrophils
- platelets zebrafish
- cancer evolution
- proteostasis
-
Edna Cukierman
Fox Chase Cancer Center, United States
- Expertise
- Cancer Biology
- Cell Biology
- Research focus
- tumor microenvironment
- fibroblastic cells
- cancer associated fibroblasts
- extracellular matrix fibrillogenesis
- extracellular matrix function
- wound healing
- fibrosis
- cancer triad
- fibroblastic cell function
- stromagenesis
- desmoplasia
- pancreatic cancer
- epithelial cancers
-
Irwin Davidson
Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS/INSERM/UDS, France
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Chromosomes and Gene Expression
- Research focus
- transcription
- chromatin
- genomics
- cancer
- Experimental organism
- human
- mouse
-
Roger J Davis
University of Massachusetts Medical School, United States
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Cell Biology
- Research focus
- diabetes
- NAFLD
- NASH
- metabolism
- insulin resistance
- cancer
- signal transduction
- Experimental organism
- mouse
- human
-
Ralph J DeBerardinis
University of Texas Southwestern Medical Center, United States
- Expertise
- Cancer Biology
- Cell Biology
- Medicine
- Research focus
- metabolism
- cancer
- genetics
- medicine
- pediatrics
- genomics
- mitochondria
- Experimental organism
- human
- mouse
-
Elisabetta Dejana
FIRC Institute of Molecular Oncology, Italy
- Expertise
- Cancer Biology
- Cell Biology
- Developmental Biology
- Research focus
- angiogenesis
- cell adhesion
- VE-cadherin
- vascular permeability
- vascular development and patterning
- endothelium
- blood brain barrier
- Experimental organism
- mouse
-
Martin Eilers
University of Würzburg, Germany
- Expertise
- Cancer Biology
- Research focus
- Myc proteins
- Myc function
- Targeting N-MYC/AURORA for tumor therapy
- Myc and Ubiquitin
- Experimental organism
- human
-
Joaquin Espinosa
University of Colorado Anschutz Medical Campus, United States
- Expertise
- Cancer Biology
- Cell Biology
- Research focus
- cancer biology
- apoptosis
- p53
- tumor suppressors
- trisomy 21
- Down syndrome
- gene expression
- chromatin
-
Eduardo Eyras
Australian National University, Australia
- Expertise
- Genetics and Genomics
- Cancer Biology
- Chromosomes and Gene Expression
- Computational and Systems Biology
- Research focus
- bioinformatics
- transcriptomics
- long-read sequencing technologies
- RNA splicing
- alternative splicing
- nanopore
-
Lydia W S Finley
Memorial Sloan Kettering Cancer Center, United States
- Expertise
- Cell Biology
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Research focus
- cell metabolism
- cancer
- stem cells
- epigenetics
- cell fate
-
Margaret Frame
University of Edinburgh, United Kingdom
- Expertise
- Cancer Biology
- Research focus
- cancer
- cell adhesion networks
- nodal tyrosine kinases
-
Michael R Green
University of Massachusetts Medical School, United States
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Medicine
- Research focus
- transcription
- pre-mRNA splicing
- cancer molecular biology
- oncology
- genetics
- functional genomics
- Experimental organism
- human
- mouse
- S. cerevisiae
-
William C Hahn
Dana-Farber Cancer Institute, United States
- Expertise
- Cancer Biology
- Genetics and Genomics
- Medicine
- Research focus
- cancer
- transformation
- functional genomics
- RAS
- YAP1
- Experimental organism
- human
-
Matthew G. Vander Heiden
Massachusetts Institute of Technology, United States
- Expertise
- Cancer Biology
- Medicine
- Research focus
- cancer biology
- biochemistry
- metabolism
- tumor microenvironment
- redox biology
- Experimental organism
- mouse
- human
-
Wenwei Hu
Rutgers University, United States
- Expertise
- Cancer Biology
- Research focus
- p53 signaling
- tumor suppressors
- cancer metabolism
- cancer cell biology
- signal transduction
- Experimental organism
- human
- mouse
-
Tony Hunter
Salk Institute for Biological Studies, United States
- Expertise
- Cancer Biology
- Cell Biology
- Research focus
- cancer
- signal transduction
- phosphorylation
- ubiquitylation
- sumoylation
- Experimental organism
- mouse
- yeast
-
Arezu Jahani-Asl
McGill University, Canada
- Expertise
- Cancer Biology
- Cell Biology
- Developmental Biology
- Research focus
- glioblastoma
- stem cells
- mitochondria
- transcription
- mental retardation
- neurodegeneration
- cancer
- Experimental organism
- mouse
-
Gou Young Koh
Institute of Basic Science and Korea Advanced Institute of Science and Technology (KAIST), South Korea
- Expertise
- Cancer Biology
- Developmental Biology
- Research focus
- angiogenesis
- lymphangiogenesis
- adipogenesis
- cardiogenesis
- vascular and cardiovascular biology
-
Ashish Lal
National Institutes of Health, United States
- Expertise
- Cancer Biology
- Biochemistry and Chemical Biology
- Chromosomes and Gene Expression
- Genetics and Genomics
- Research focus
- RNA biology
- lncRNAs
- microRNAs
- gene regulation
- cancer biology
- p53
- Experimental organism
- human
-
Beate Lichtenberger
Medical University of Vienna, Austria
- Expertise
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Research focus
- Cancer-associated fibroblasts (CAFs)
- fibroblast-mediated skin pathologies
- skin cancer
- stem cell fate decisions
- Experimental organism
- human
- mouse
-
Yuting Ma
Suzhou Institute of Systems Medicine, China
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Cell Biology
- Research focus
- tumor immunology
- immunotherapy
- tumor microenvironment
- stress responses
- neuroendocrine-immune crosstalk
- cell death
-
Kay F Macleod
University of Chicago, United States
- Expertise
- Cell Biology
- Cancer Biology
- Research focus
- autophagy
- mitochondria
- pancreatic cancer
- breast cancer
- liver homeostasis
- tumor metabolism
- Experimental organism
- mouse
- human
-
Jean-Christophe Marine
Vlaams Instituut voor Biotechnologie, Belgium
- Expertise
- Cancer Biology
- Genetics and Genomics
- Research focus
- mouse genetics
- molecular oncology
- cancer genomics
- Experimental organism
- mouse
-
Grant McArthur
Peter MacCallum Cancer Centre, Australia
- Expertise
- Cancer Biology
- Medicine
- Research focus
- melanoma
-
Martin McMahon
University of Utah, United States
- Expertise
- Cancer Biology
- Research focus
- mouse models
- signal transduction
- RAS
- BRAF
- PI3-kinase
- Experimental organism
- mouse
-
Goutham Narla
University of Michigan, United States
- Expertise
- Medicine
- Cancer Biology
- Genetics and Genomics
- Research focus
- cancer therapeutics
- cancer genetics
- small molecule drug development
- protein phosphatase
- Experimental organism
- human
- mouse
-
Duojia Pan
UT Southwestern Medical Center, United States
- Expertise
- Cancer Biology
- Cell Biology
- Research focus
- growth control
- tumor suppressors
- oncogenes
- Hippo signaling
- transcription
- regeneration
- Experimental organism
- D. melanogaster
- mouse
-
Maddy Parsons
King's College London, United Kingdom
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Cell Biology
- Physics of Living Systems
- Research focus
- adhesion
- migration
- cytoskeleton
- receptor signalling
- extracellular matrix
- fibrosis
- cancer
- Experimental organism
- mouse
-
Renata Pasqualini
Rutgers University, United States
- Expertise
- Medicine
- Cancer Biology
- Research focus
- radiation oncology
- translational cancer research
- prostate cancer
- vascular biology
-
Lynne-Marie Postovit
University of Alberta, Canada
- Expertise
- Cancer Biology
- Cell Biology
- Stem Cells and Regenerative Medicine
- Research focus
- cellular plasticity
- tumour microenvironment
- hypoxia
- stem cells
- metastasis
- ovarian cancer
- breast cancer
-
Daniela Robles-Espinoza
International Laboratory for Human Genome Research, Mexico
- Expertise
- Cancer Biology
- Genetics and Genomics
- Research focus
- melanoma
- bioinformatics
- telomeres
- acral lentiginous melanoma
- sequencing
-
Jody Rosenblatt
King's College London, United Kingdom
- Expertise
- Cell Biology
- Cancer Biology
- Research focus
- apoptosis
- mitosis
- cell extrusion
- epithelial
- homeostasis
- morphogenesis
- cancer cell biology
-
Charles Sawyers
Memorial Sloan-Kettering Cancer Center, United States
- Expertise
- Cancer Biology
- Medicine
- Research focus
- translational medicine
- oncology
- Experimental organism
- human
-
Katharina Schlacher
UT MD Anderson Cancer Center, United States
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Research focus
- DNA replication
- genome instability
- BRCA2
- p53
- PTEN
- homologous recombination
- DNA repair
-
Jeffrey Settleman
Pfizer, United States
- Expertise
- Cancer Biology
- Research focus
- cancer cell biology
- signal transduction
- tumor heterogeneity
- signaling
- epigenetics
-
Nima Sharifi
Cleveland Clinic, United States
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Medicine
- Research focus
- steroid biochemistry
- steroid metabolism
- prostate cancer
- nuclear receptors
- hormone therapy resistance
- androgens
- oncology
- Experimental organism
- mouse
-
Maria Spies
University of Iowa, United States
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Chromosomes and Gene Expression
- Structural Biology and Molecular Biophysics
- Research focus
- single-molecule biophysics
- DNA repair
- DNA replication
- DNA recombination
- genome stability
- protein dynamics
- protein-nucleic acids interactions
- drug discovery
- Experimental organism
- human
- yeast
- bacteria
-
Margaret Stanley
University of Cambridge, United Kingdom
- Expertise
- Cancer Biology
- Microbiology and Infectious Disease
- Medicine
- Epidemiology and Global Health
- Research focus
- vaccines
- cervix cancer
- cervix precancer
- keratinocyte biology
- human papillomavirus
- DNA viruses
- vaccine immunology
- Experimental organism
- human
-
Ivan Topisirovic
Jewish General Hospital, Canada
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Cell Biology
- Research focus
- mRNA translation
- signaling
- metabolic regulation
- protein quality control
- Experimental organism
- mouse
- human
-
Alfonso Valencia
Barcelona Supercomputing Center, Spain
- Expertise
- Cancer Biology
- Computational and Systems Biology
- Research focus
- bioinformatics
- computational biology
- structural bioinformatics
- co-evolution
- cancer genomics
- text mining
-
Eric J Wagner
University of Texas Medical Branch at Galveston, United States
- Expertise
- Chromosomes and Gene Expression
- Biochemistry and Chemical Biology
- Cancer Biology
- Genetics and Genomics
- Research focus
- RNA biology
- transcription
- RNA processing
- gene expression
-
Jian Xu
University of Texas Southwestern Medical Center, United States
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Developmental Biology
- Genetics and Genomics
- Stem Cells and Regenerative Medicine
- Research focus
- hematopoiesis
- erythropoiesis
- myeloid leukemia
- epigenetics
- transcription regulation
- enhancer
- metabolism
- Experimental organism
- human
- mouse
-
Norma Ybarra
Research Institute McGill University Health Center, Canada
- Expertise
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Research focus
- radiation biology
- radiotherapy
- cancer cell metabolism
- cancer therapies
-
Hao Zhu
University of Texas Southwestern Medical Center, United States
- Expertise
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Medicine
- Research focus
- mechanisms of tissue repair and organ regeneration
- liver cancer
- hepatocellular carcinoma
- epigenetics
- polyploidy
- Experimental organism
- human
- mouse
-
Wilbert Zwart
Netherlands Cancer Institute, Netherlands
- Expertise
- Cancer Biology
- Medicine
- Research focus
- breast cancer
- prostate cancer
- hormonal regulation
- epigenetics
- transcription factors
- genomic profiling
- Experimental organism
- human
